Skip to main content

Advertisement

SpringerLink
Log in

When should we delay highly active antiretroviral therapy?

  • Editorials
  • Published:
Journal of General Internal Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–60. See comments.

    Article  PubMed  Google Scholar 

  2. Centers for Disease Control and Prevention. Update: trends in AIDS incidence—United States, 1996. MMWR. 1997;46:861–7.

    Google Scholar 

  3. Centers for Disease Control and Prevention. HIV AIDS Surveillance Report. December 1998. Washington, DC: US Department of Health and Human Services; 1999.

    Google Scholar 

  4. Fairfield KM, Libman H, Davis RB, Eisenberg DM, Phillips RS. Delays in protease inhibitor use in clinical practice. J Gen Intern Med. 1999;14:395–401.

    Article  PubMed  CAS  Google Scholar 

  5. Johnson PA, Lee TH, Cook EF, Rouan GW, Goldman L. Effect of race on the presentation and management of patients with acute chest pain. Ann Intern Med. 1993;118:593–601.

    PubMed  CAS  Google Scholar 

  6. Maynard C, Fisher LD, Passamani ER, Pullum T. Blacks in the coronary artery surgery study (CASS): race and clinical decision making. Am J Public Health. 1986;76:1446–8.

    PubMed  CAS  Google Scholar 

  7. Todd KH. Pain assessment and ethnicity. Ann Emerg Med. 1996;27:421–3.

    Article  PubMed  CAS  Google Scholar 

  8. Moore RD, Bone LR, Geller G, Mamon JA, Stokes EJ, Levine DM. Prevalence, detection, and treatment of alcoholism in hospitalized patients. JAMA. 1989;261:403–7.

    Article  PubMed  CAS  Google Scholar 

  9. Powe NR, Griffiths RI, de Lissovoy G, et al. Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval. JAMA. 1992;268:1434–40.

    Article  PubMed  CAS  Google Scholar 

  10. Diehr P, Yergan J, Chu J, et al. Treatment modality and quality differences for black and white breast-cancer patients treated in community hospitals. Med Care. 1989;27:942–58.

    Article  PubMed  CAS  Google Scholar 

  11. Moore RD, Stanton D, Gopalan R, Chaisson RE. Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med. 1994;330:763–8.

    Article  PubMed  CAS  Google Scholar 

  12. Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998;280:547–9.

    Article  PubMed  CAS  Google Scholar 

  13. Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA. 1998;280:544–6.

    Article  PubMed  CAS  Google Scholar 

  14. Vanhove GF, Schapiro JM, Winters MA, Merigan TC, Blaschke TF. Patient compliance and drug failure in protease inhibitor monotherapy. JAMA. 1996;276:1955–6. Letter.

    Article  PubMed  CAS  Google Scholar 

  15. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy. The Netherlands, Canada and Australia Study. JAMA. 1998;279:930–7.

    Article  PubMed  CAS  Google Scholar 

  16. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA. 1998;279:1977–83.

    Article  PubMed  CAS  Google Scholar 

  17. Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med. 1998;339:307–11.

    Article  PubMed  CAS  Google Scholar 

  18. Conlon CP, Klenerman P, Edwards A, Larder BA, Phillips RE. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. J Infect Dis. 1994;169:411–5.

    PubMed  CAS  Google Scholar 

  19. Imrie A, Beveridge A, Genn W, Vizzard J, Cooper DA. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group. J Infect Dis. 1997;175:1502–6.

    PubMed  CAS  Google Scholar 

  20. Donovan R, Berrey M, Corey L, Mayers D. Prevalence of Protease Inhibitor and Reverse Transcriptase Inhibitor Resistance Mutations in Recent HIV-1 Seroconverters in Seattle. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill, 1999.

  21. Boden D, Hurley A, Zhang L, et al. Prevalence of HIV-1 drug resistance mutations in newly infected individuals remains stable over a 3 year period. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill, 1999.

  22. Ziegelstein RC, Bush DE, Fauerbach JA. Depression, adherence behavior, and coronary disease outcomes. Arch Intern Med. 1998;158:808–9. Letter.

    Article  PubMed  CAS  Google Scholar 

  23. Carney RM, Freedland KE, Eisen SA, Rich MW, Jaffe AS. Major depression and medication adherence in elderly patients with coronary artery disease. Health Psychol. 1995;14:88–90.

    Article  PubMed  Google Scholar 

  24. Carney RM, Freedland KE, Eisen SA, Rich MW, Skala JA, Jaffe AS. Adherence to a prophylactic medication regimen in patients with symptomatic versus asymptomatic ischemic heart disease. Behav Med. 1998;24:35–9.

    Article  PubMed  CAS  Google Scholar 

  25. Mohr DC, Goodkin DE, Likosky W, Gatto N, Baumann KA, Rudick RA. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol. 1997;54:531–3.

    PubMed  CAS  Google Scholar 

  26. Cochrane GM. Compliance and outcomes in patients with asthma. Drugs. 1996;52:12–9.

    PubMed  Google Scholar 

  27. Everett KD, Brantley PJ, Sletten C, Jones GN, McKnight GT. The relation of stress and depression to interdialytic weight gain in hemodialysis patients. Behav Med. 1995;21:25–30.

    Article  PubMed  CAS  Google Scholar 

  28. Sensky T, Leger C, Gilmour S. Psychosocial and cognitive factors associated with adherence to dietary and fluid restriction regimens by people on chronic haemodialysis. Psychother Psychosomat. 1996;65:36–42.

    Article  CAS  Google Scholar 

  29. Singh N, Squier C, Sivek C, Wagener M, Nguyen MH, Yu VL. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care. 1996;8:261–9.

    Article  PubMed  CAS  Google Scholar 

  30. Patterson D, Swindells S, Mohr J, et al. How Much Adherence is Enough? A Prospective Study of Adherence to Protease Inhibitor Therapy Using MEMSCaps. Presented at the 6th Conference on Retrovirus and Opportunistic Infections, Chicago, Ill, 1999.

  31. Ferrando SJ, Wall TL, Batki SL, Sorensen JL. Psychiatric morbidity, illicit drug use and adherence to zidovudine (AZT) among injection drug users with HIV disease. Am J Drug Alcohol Abuse. 1996;22:475–87.

    PubMed  CAS  Google Scholar 

  32. Pablos-Mendez A, Knirsch CA, Barr RG, Lerner BH, Frieden TR. Nonadherence in tuberculosis treatment: predictors and consequences in New York City. Am J Med. 1997;102:164–70.

    Article  PubMed  CAS  Google Scholar 

  33. Caminero JA, Pavon JM, Rodriguez de Castro F, et al. Evaluation of a directly observed six months fully intermittent treatment regimen for tuberculosis in patients suspected of poor compliance. Thorax. 1996;51:1130–3.

    Article  PubMed  CAS  Google Scholar 

  34. Marco A, Cayl JA, Serra M, et al. Predictors of adherence to tuberculosis treatment in a supervised therapy programme for prisoners before and after release. Study Group of Adherence to Tuberculosis Treatment of Prisoners. Eur Respir J. 1998;12:967–71.

    Article  PubMed  CAS  Google Scholar 

  35. Tulsky J, Pilote L, Hahn J, Charlebois E, Chesney M, Moss AR. Adherence to TB prevention in the homeless. Presented at the American Thoracic Society Meeting, Chicago, Ill, 1999.

  36. Freeman RC, Rodriguez GM, French JF. Compliance with AZT treatment regimen of HIV-seropositive injection drug users: a neglected issue. AIDS Educ Prev. 1996;8:58–71.

    PubMed  CAS  Google Scholar 

  37. Samet JH, Libman H, Steger KA, et al. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. Am J Med. 1992;92:495–502.

    Article  PubMed  CAS  Google Scholar 

  38. Singh N, Berman S, Swindells S, et al. Adherence to antiretroviral therapy in HIV infected patients: impact of demographic, psychosocial, and medical regimen related variables. Presented at the International Disease Society of America annual meeting, Denver, Colo, 1998.

  39. Haubrich R, Little S, Dube M, et al. Self-reported treatment adherence and drug/alcohol use are associated with virologic outcomes in CCTG 570: a clinical strategy trial of HIV antiretroviral monitoring. Presented at the 12th World AIDS Conference, Geneva, Switzerland, 1998.

  40. Newman RG, Whitehill WB. Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet. 1979;2:485–8.

    Article  PubMed  CAS  Google Scholar 

  41. Dole VP, Robinson JW, Orraca J, Towns E, Searcy P, Caine E. Methadone treatment of randomly selected criminal addicts. N Engl J Med. 1969;280:1372–5.

    Article  PubMed  CAS  Google Scholar 

  42. Mulvaney FD, Alterman AI, Boardman CR, Kampman K. Cocaine abstinence symptomatology and treatment attrition. J Subst Abuse Treat. 1999;16:129–35.

    Article  PubMed  CAS  Google Scholar 

  43. Maude-Griffin PM, Hohenstein JM, Humfleet GL, Reilly PM, Tusel DJ, Hall SM. Superior efficacy of cognitive-behavioral therapy for urban crack cocaine abusers: main and matching effects. J Consult Clin Psychol. 1998;66:832–7.

    Article  PubMed  CAS  Google Scholar 

  44. Siqueland L, Crits-Christoph P, Frank A, et al. Predictors of dropout from psychosocial treatment of cocaine dependence. Drug Alcohol Depend. 1998;52:1–13.

    Article  PubMed  CAS  Google Scholar 

  45. Cantwell B, McBride AJ. Self detoxication by amphetamine dependent patients: a pilot study. Drug Alcohol Depend. 1998;49:157–63.

    Article  PubMed  CAS  Google Scholar 

  46. Hando J, Topp L, Hall W. Amphetamine-related harms and treatment preferences of regular amphetamine users in Sydney, Australia. Drug Alcohol Depend. 1997;46:105–13.

    Article  PubMed  CAS  Google Scholar 

  47. Cameron DW H-CM, Kravick S, et al. The advanced HIV Ritonavir Study Group: prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with Ritonavir update. Presented at the 11th International Conference of AIDS. Vancouver, Canada, 1996.

  48. Bangsberg D, Tulsky JP, Hecht FM, Moss AR. Protease inhibitors in the homeless. JAMA. 1997;278:63–5.

    Article  PubMed  CAS  Google Scholar 

  49. Gulick R, Mellors J, Havlir D, et al. Treatment with Indinavir (IDV), Zidovudine (ZDV), and Lamivudine (3TC): three-year follow-up. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill, 1999.

  50. Rosenberg E. Preserving HIV-1 specific T-cell help: will it prevent progression? Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill. 1999.

  51. Autran B. Effects of antiretroviral therapy on immune reconstitution. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill, 1999.

  52. Gilbert JR, Evans CE, Haynes RB, Tugwell P. Predicting compliance with a regimen of digoxin therapy in family practice. Can Med Assoc J. 1980;123:119–22.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Epidemiology and Prevention Intervention Center, San Francisco General Hospital, Calif

    David R. Bangsberg MD, MPH

  2. Department of Epidemiology and Biostatistics, University of California, San Francisco, Calif

    Andrew Moss PhD

Authors
  1. David R. Bangsberg MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew Moss PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bangsberg, D.R., Moss, A. When should we delay highly active antiretroviral therapy?. J GEN INTERN MED 14, 446–448 (1999). https://doi.org/10.1046/j.1525-1497.1999.05109.x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1046/j.1525-1497.1999.05109.x

Search

Navigation